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Abstract
Background—The development of prostate cancer can be influenced by genetic and
environmental factors. Numerous germline SNPs influence prostate cancer susceptibility. The
functional pathways in which these SNPs increase prostate cancer susceptibility are unknown.
Finasteride is currently not being used routinely as a chemoprevention agent but the long term
outcomes of the PCPT trial are awaited. The outcomes of the SELECT trial have not
recommended the use of chemoprevention in preventing prostate cancer. This study investigated
whether germline risk SNPs could be used to predict outcomes in the PCPT and SELECT trial.
Methods—Genotyping was performed in European men entered into the PCPT trial (n=2434)
and SELECT (n=4885). Next generation genotyping was performed using Affymetrix® Eureka™
Genotyping protocols. Logistic regression models were used to test the association of risk scores
and the outcomes in the PCPT and SELECT trials.
Results—Of the 100 SNPs, 98 designed successfully and genotyping was validated for samples
genotyped on other platforms. A number of SNPs predicted for aggressive disease in both trials.
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Men with a higher polygenic score are more likely to develop prostate cancer in both trials, but the
score did not predict for other outcomes in the trial.
Conclusion—Men with a higher polygenic risk score are more likely to develop prostate cancer.
There were no interactions of these germline risk SNPs and the chemoprevention agents in the
SELECT and PCPT trials.
Introduction
Prostate cancer accounts for a quarter of cancer diagnoses in men in the UK and is the fourth
most common cancer worldwide with an estimated 1.1 million men diagnosed in 2012 (1).
Screening strategies have not led to their routine clinical use in daily practice, due to an
over-diagnosis of indolent cancers (2).
Due to its biology, prostate cancer is ideally suited target for chemoprevention because of its
step-wise biological development. Prostate cancer may have precursor lesions such as
atypical small acinar proliferation and high grade prostatic intraepithelial neoplasia which
may appear many years before cancer is diagnosed. This high risk population with these
precursor lesions could be targeted for chemoprevention (3). Prostate cancer also has a long
latent period from its development to its eventual clinical manifestation. Chemoprevention
could also be used to prevent these early malignant lesions developing further and therefore
many men could be spared diagnostic procedures and potentially toxic systemic treatments
(4).
It is thought that the risk of prostate cancer development could be potentially modifiable by
dietary and other lifestyle factors. Large epidemiological studies have shown that migrants
who have moved from areas of low prostate cancer incidence such as Korea and Japan to the
USA have developed prostate cancer rates similar to their native inhabitants (5, 6).
Environmental factors are attributable to this change of risk and some of these could be
potentially modifiable by dietary changes (6). There are also causal links between androgen
exposure and the development of prostate cancer, which is also potentially modifiable (7).
The need to answer the question of the role of chemoprevention in prostate cancer was the
aim of 2 large randomised controlled trials: The Prostate cancer Prevention Trial (PCPT)
and The Selenium and Vitamin E Cancer Prevention Trial (SELECT). The biological
rationale for the agents used in the trial, trial schema and results can be found in more detail
elsewhere (8, 9). In summary, 18,880 men were eligible and randomized on the PCPT to
receive placebo or finasteride. The results of the PCPT trial showed that Prostate cancer was
detected in 803 of the 4368 men in the finasteride group and 1147 of the 4692 men in the
placebo group who had data for analyses. There was a 24.8% reduction in prevalence over
the seven-year period. Tumours with a Gleason score 7–10 were more common in the
finasteride group (280 of 757 tumours (37.0%), than in the placebo group (237 of 1068
tumours (22.2 percent) (P<0.001 for the comparison between groups) (8). The long term
results of the PCPT trial showed that the 10 year survival from prostate cancer was
equivalent between the 2 groups (10).
In the SELECT trial, 35,533 men were randomised to receive selenium or vitamin E, or both
or neither. The SELECT trial was closed early because the interim analysis showed that
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neither selenium, vitamin E, nor the combination prevented prostate cancer. The long term
results of the SELECT trial showed that men taking vitamin E had increased incidence of
prostate cancer compared with placebo, which was statistically significant (9). Genetic
variations influencing the effects of these chemoprevention agents have been reported from
the PCPT and SELECT trials (11–14). However these studies have only used a candidate
gene approach to look for association in comparison with our study which has followed up
validated risk single nucleotide polymorphisms.
At the time of undertaking these analyses, 100 germline risk single nucleotide
polymorphisms (SNPs) had been identified in genome wide association studies (15, 16). The
100 SNPs account for approximately 33% of familial risk of prostate cancer (16). If
polygenic risk scores are calculated, the top 10% of men in the highest risk stratum have an
approximately 2.9-fold relative risk of prostate cancer compared with the average of the
population, whilst the top 1% of men have a 5.7-fold relative risk in comparison with the
population average (16). If these polygenic SNP scores could be incorporated into screening
with the addition of known risk factors (age, race, family history), then men with the highest
risk of prostate cancer development could be targeted for more intensive screening or
intervention.
Traditional genotyping technologies are currently not suited to provide fast accurate outputs
that could be used in prospective clinical trials (17). Genotype calling from next generation
sequence techniques may be able to overcome these issues and therefore be more suited for
everyday clinical use (18). We have worked with Eureka Genomics (Hercules, California;
previously affymetrix now ThermoFisher Scientific) to design and validate a next generation
genotyping assay in these analyses.
While the functional role of how these SNPs influence cancer predisposition is under
investigation, evidence suggests that this may be through various pathways (19). Therefore,
the hypothesis underlying this study was that common genetic variants involved in prostate
cancer pre-disposition may have a role in tumour formation but also influence the effects of
the chemoprevention agents. In breast cancer, evidence has shown that chemoprevention
with tamoxifen reduces the risk of contralateral breast cancer for those women who have
variants in the BRCA2 gene (20). The aim of this study was to investigate the association of
prostate cancer germline risk SNPs and their influence on the chemoprevention agents in the
PCPT and SELECT trials.
Materials and Methods
Patients
The details of the PCPT study can be found in more detail elsewhere (8). Informed consent
as obtained from all patients. In summary, healthy men aged 55 years or older, with a
normal digital rectal examination (DRE), American Association Urology Score of less than
20 and no clinically significant co-morbidity were entered into the trial. The prostate
specific antigen (PSA) on entry into the trial was required to be 3.0ng/ml or lower. Men
were randomised to receive Finasteride or placebo. The men underwent annual DRE, and
measurements of PSA. If the DRE was suspicious for cancer or the adjusted PSA > 4.0
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ng/ml, then these men were recommended to undergo a prostate biopsy. If these
investigations were normal or biopsy was negative, men were followed up for a total of 7
years and an end of study biopsy was performed. The end of study biopsy identified
additional prostate cancers among men with neither a sspicious DRE or elevated PSA and
confirmed that the controls did not have prostate cancer. A total of 18,880 eligible men were
randomised into the trial. Our institution received DNA samples from 2434 cases and
controls from the PCPT study.
The details of the SELECT trial can found in more detail elsewhere (21). Healthy men
entered the study and were aged 55 years or over (Afro-American men were aged 50 or
older), had a normal DRE and a PSA ≤4ng/ml. Participants were randomised into one of 4
groups: Selenium alone, Vitamin E alone, Selenium and Vitamin E or placebo. Men were
followed every 6 months and suggested to have an annual DRE and PSA. Men were
recommended to undergo PSA and DRE testing and prostate biopsy based on local care
guidelines. Upon a diagnosis of prostate cancer, men were monitored annually.
A total of 35,553 men were randomised into the trial. Our institution received DNA samples
from 4885 men, which were samples that were selected to be analysed as part of a case-
cohort study.
Laboratory Methods, Genotyping and Quality Control
DNA was collected by white blood cells from participants in the PCPT and SELECT trials
and extracted at the National Cancer Institute (22). 30µl of DNA was received at The
Institute of Cancer Research; 5µl was sent for genotyping for the purpose of this analysis.
At the time of designing the genotyping assay the latest 100 SNP panel was used (23).
Supplementary table 2 lists the 100 known prostate cancer susceptibility SNPs at that time.
The 100 SNP panel was developed by Affymetrix®, now a part of ThermoFisher Scientific.
The samples were genotyped using the Affymetrix® Eureka™ Genotyping protocols. The
Eureka genotyping assay is a ligation-dependent PCR reaction, which uses interrogation site
bar codes contained within the ligation probes, as well as sample index bar codes added
during the amplification step. Next generation sequencing libraries were created and short
cycle sequence data were generated from the prepared libraries. Analysis software was used
to tabulate the number of reads that contain each combination of sample, locus and allele bar
code (as appropriate). The genotype was determined by in-house software using
Affymetrix® Eureka™ protocols.
In order to validate this new genotyping technique two methods were used. Firstly, known
genotypes of overlapping samples from the iCOGs custom array and the Affymetrix panel
were contrasted (24). Secondly the observed minor allele frequencies from the Affymetrix
panel were compared with the genotypes of overlapping samples on a custom high-
throughput array by case and control status (25). The minor allele frequencies between the
two techniques were highly correlated (r2 > 0.99).
Standard quality control measures were applied to remove variants with missing rates >10%
or displayed genotype frequency deviating from those expected under Hardy-Weinberg
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equilibrium (P<0.05). Samples with less than 90% genotyping rate were also removed Table
3.
Measured Outcome
On entry into the PCPT and SELECT trials, phenotypic information was collected on all
participants; further detailed information on the phenotypic information collected can be
found in the individual trial protocols (26, 27).
Men who self-reported to be of European origin were only included in this study as the vast
majority of the germline SNPs used in this analysis were discovered in GWAS from
populations of European descent. Family history (FHx) was defined as men who had one or
more first degree relatives affected with prostate cancer. Biopsies that were positive for
prostate cancer were reviewed by the local pathologist at the participating centre, and for the
PCPT trial and also reviewed centrally (8, 21). High grade prostate cancer (non-indolent
prostate cancer) was defined as a Gleason score ≥ 7. A summary of basic phenotype
information for the DNA received from PCPT and SELECT can be found here Table 1.
Statistical Analysis
A polygenic risk score was calculated by summing the genotype dosage for all variants for
an individual. The log-odds ratios used to weight the risk score were taken from the
OncoArray Meta-analysis (28). Two types of risk score were calculated:
Non−weighted, for patient �: ���� ������ = ∑1� ���
Weighted, for patient �: ����ℎ��� ���� ������ = ∑1� �����
j = variants 1 – 100
βj = is the per allele log-odds ratio for the risk of prostate cancer associated with variant j
G = risk allele dosage
Within each cohort of both trials age and body mass index (BMI) were equally distributed.
Logistic regression was used to test the association of case/control and Gleason score and
the polygenic risk score. Family history was also used as a covariate in the analyses. The
polygenic risk score was divided into quartiles for the logistic regression model and
interaction tested. For each individual SNP the χ2 test was used to test the association with
overall prostate cancer and sub-strata defined by Gleason grade. Statistical significance was
determined at a level of P<0.05. All analyses were performed in the statistical package R
3.2.2 (29).
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Power Calculations
The power was calculated using the MAF and OR from the Oncoarray paper which was the
largest GWAS performed to date (30). A significance level of α =0.05 was used and
calculated using a genetic power calculator (31). The results can be seen in supplementary
table 1. The power ranged for PCPT (5–96%) and SELECT (5–99%). The power was
greater in the SELECT trial as there were greater number of participants the PCPT. Overall
the study was underpowered however there was a correlation between those with a high
power and the signal seen of the SNP in PCPT/SELECT. A multiple comparison adjustment
was not performed as known variants were analysed in PCPT/SELECT. Power was not
calculated by randomization arm as the power would have been too low.
Results
The characteristics of the participants of the trial are summarised in Table 1. Of the 100
SNPs, 98 SNPs were designed successfully. Non-Europeans were removed from the analysis
and summary of the quality control is shown in Table 3.
The single SNP association in both trials shows multiple SNPs that are associated with
developing prostate cancer at a pre-defined significance level of P<0.05 (Figure 1, Figure 2,
Figure 3 (Table 3,Table 4). In the PCPT trial rs4430796 is associated in the finasteride arm
with development of prostate cancer; the SNP resides near the gene HNF1B. There are also
multiple SNPs which are significant for the association with high grade and low grade
Gleason score (Table 4). In the PCPT trial as the polygenic risk score increases the beta
predicting prostate cancer outcome increases and this is statistically significant. With the
addition of Finasteride the beta reduces but it is not statistically significant (Table 6). In the
SELECT trial the polygenic risk score did not predict cancer outcome except for those men
who are in group 4 of the weighted risk score. There was no interaction between the
interventions in the PCPT and SELECT trials and the polygenic risk score.
In the PCPT trial, the use of drug intervention did predict the outcome of developing high
grade prostate cancer, but the chemopreventions in the SELECT trial were null (Table 7).
The weighted polygenic risk score was consistently higher in cases than controls in all
groups and this was also statistically significant (P<0.05) in both PCPT and SELECT trials
(Figure 4, Figure 5). Men in the study who had a first degree relative with prostate cancer
had a higher polygenic SNP score in both studies, but this was not statistically significant
(P>0.05).
Discussion
This study confirmed that men in both the PCPT and SELECT trials who developed prostate
cancer had a higher polygenic risk score than men who didn’t develop prostate cancer. The
study found no evidence that a high polygenic risk score in combination with other risk
factors such as family history could predict if the drug interventions could reduce prostate
cancer incidence or development of high grade prostate cancer. Some individual SNPs were
detected to predict the likelihood of developing cancer in the individual study arms but these
analyses were limited by the power. Rare variants such as those found in sequencing of
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BRCA1 and BRCA2 were not included in this analysis as they require sequencing rather than
genotyping in larger cohorts using different statistical analyses. This study was limited to
prostate cancer risk associated with common variants of European ancestry and is not
useable in other ethnic groups.
The results of the PCPT trial showed a 24.8% reduction in prostate cancer, but the
chemoprevention in the SELECT trial dud bit reduce prostate cancer incidence (8, 9).
Prostate cancer SNPs are mostly found in intronic regions of genes, and therefore
functionally it is not clear how these SNPs increase prostate cancer risk.
Genetic variations in the pathways in which the chemoprevention agents act may influence
the efficacy of the agent. Finasteride acts by inhibiting the enzyme 5α reductase which is
mediated by genes of the SRF5A family (32). Polymorphisms in the SRFA genes have been
reported which affect the efficacy of Finasteride (33, 34). Genetic variations in the
selenoprotein genes impact on plasma selenium levels, and recent evidence suggests that this
may be associated with locally advanced or aggressive prostate cancer (14). Variations in
vitamin E levels may also be modified by genetic variations in vitamin E related genes and
an association between these and a lower incidence of prostate cancer has been found (12).
If the above mechanisms that affect the outcome of these chemoprevention agents were in
common functional pathways with the prostate cancer risk SNPs, men in the highest
polygenic risk score would be more likely to see some of the above benefits from
chemoprevention. Many of the pathways in which these genetic variants affect drug efficacy
remain unknown, which therefore could be accounting for the null results of this study.
In the single SNP association for the development of prostate cancer a number of SNPs pass
the significance level. Functionally it is not clear how these associations are linked but there
are potentially some interesting regions. One interesting SNP which was statistically
significant in the Finasteride arm of the PCPT trial was rs4430796 which resides near the
gene HNF1B (35). This SNP is in strong linkage disequilibrium with SNP rs757210. It has
been reported that inheriting the risk allele for one of these SNPs increases the likelihood of
developing prostate cancer (OR =1.22, 95% CI 1.15 – 1.30; P=1.4×10−11), but reduces the
risk of developing type 2 diabetes (OR=0.91, 95% CI 0.88–0.93; P=8×10−10) (36). The
association between the phenotypes of type 2 diabetes and prostate cancer was further
investigated in the PCPT trial. This showed that type 2 diabetes was associated with a 47%
reduction of low grade prostate cancer and 28% reduction of high grade prostate cancer (37).
When the authors looked at the association of obesity and prostate cancer they found that
increased obesity reduced low grade prostate cancer but increased high grade prostate cancer
(37).The authors also showed that there was no correlation between obesity and type 2
diabetes, suggesting an independent pathway in which diabetes protects against prostate
cancer. Our analysis supports these data which shows that diabetes incidence is lower in
men who develop prostate cancer in the placebo arm and inherit one of the SNPs near
HNF1B. However this association is not seen in men who have Finasteride who have higher
rates of type 2 diabetes and could possibly suggest a metabolic interaction between the drug
and the SNP.
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On analyses of the SNP association with high grade and low grade Gleason score a number
of SNPs show an association with Gleason grade in the individual trial arms. An example in
the Finasteride arm of the PCPT, SNP rs7127900 showed a statistically significant reduction
in the odds ratio of developing high grade prostate cancer (P=0.04, OR = 0.67). Interestingly
SNP rs7127900 has been shown to have a biological interaction with insulin-like-growth-
factor-2 (IGF-2) (38). Analyses from the PCPT trial have shown that serum levels of IGF
were not correlated with prostate cancer development; however men who have high levels of
IGF are more likely to be on anti-diabetic drugs such as metformin which have shown to
have anti-cancer properties (39). In the SELECT trial SNP rs12621278 in the Vitamin E arm
was also associated with a reduced odds ratio of developing high grade prostate cancer. The
SNP rs12621278 resides near the integrin gene ITGA6 which has been shown to be
associated with prostate cancer progression and development (40). Vitamin E could possibly
be interacting with this pathway (41).
So far 33% of common genetic variants that predict the familial risk of prostate cancer have
been discovered (42). Men in the top 1% risk distribution have a 5.7 fold relative risk of
developing prostate cancer compared with the average population being profiled (24). The
National Institutes of Health GAME-ON initiative has discovered a further 63 new prostate
cancer susceptibility SNPs. Further work needs to be performed to understand if these new
SNPs will help understand the biological rationale for chemoprevention (28)
In summary this work has showed that a high polygenic risk score can predict the
development of prostate cancer but there is no interaction with chemoprevention agents such
as finasteride and selenium/vitamin E. This is an important null finding as population risk
stratification will be undertaken in coming years for disease detection and prevention
strategies. There is therefore no evidence from these results that certain risk groups are
individually more likely to benefit from these two types of chemoprevention and other types
of agent will need to be tested to try to reduce risk of high grade cancers in men with higher
polygenic risk scores.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1–.
Manhattan plot showing the single SNP association of the placebo (above) and finasteride
(below) arms in PCPT. Blue line represents significance level P=0.05.
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Figure 2 -
Manhattan plot showing the single SNP association of the placebo (above) and selenium
(below) arms in SELECT. Blue line represents significance level P=0.05.
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Figure 3 -
Manhattan plot showing the single SNP association of the vitamin E (above) and selenium
and vitamin E (below) arms in SELECT. Blue line represents significance level P=0.05.
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Figure 4 -
Boxplot showing the weighted polygenic risk score which is higher in cases than controls
and is statistically significant (P<0.05) in the PCPT trial.
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Figure 5 -
Boxplot showing the weighted polygenic risk score which is higher in cases than controls
and is statistically significant (P<0.05) in the SELECT trial.
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Table 1 –
Patient Characteristics (FHx – family history)
PCPT   SELECT
Finasteride Placebo   Placebo Selenium Vitamin E Selenium & Vitamin E
Numbers
Total 833 1256 845 816 908 829
Cases 428 616 352 330 393 346
Control 405 640 493 486 515 483
 
Age
Mean age of entry trial (SD) 64.4 (5.7) 63.6 (5.6) 63.9 (6.0) 63.8 (6.0) 64.0 (6.1) 63.7 (6.2)
Mean age of Ca Dx (SD) 69.9 (5.6) 69.7 (5.7) 67.1(5.8) 63.8 (6.0) 67.6 (6.1) 67.2 (6.2)
 
BMI (kg/m2) 27.5 27.4 NA NA NA NA
 
 
FHx Positive 195 263 180 149 188 178
 
Gleason ≤ 6 266 470 197 182 221 202
Gleason ≥ 7 157 138 123 115 143 114
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Table 2 –
Quality control for both studies
PCPT SELECT
Number of SNPs Genotyped 98 98
Total number of DNA Samples Received 2435 4789
 
European 2089 3512
 
>10% Genotype Missing for individual lost
Cases 0 47
Controls 0 67
 
SNP lost with Less than 90% genotyping rate 5 9
 
Hardy-Weinberg Equilibrium SNPs lost (P<0.001) 0 0
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Table 3 –
Showing the significant single SNP association for the development of prostate cancer and nearby genes in
PCPT trial
Trial Arm Chromosome SNP P Value Odds Ratio Nearby Genes
Placebo 3 rs7611694 0.04367 0.8473 SIDT1
Placebo 7 rs12155172 0.007637 1.292 SP8
Placebo 8 rs6983267 0.00198 0.78 N/A
Placebo 17 rs1859962 0.003917 1.26 N/A
Finasteride 2 rs7584330 0.03174 0.7799 MLPH
Finasteride 8 rs16901979 0.008784 2.28 N/A
Finasteride 17 rs4430796 9.64E-05 1.489 HNF1B
Finasteride 17 rs684232 0.03556 1.241 VPS53, FAM57A
Finasteride 17 rs1859962 0.01778 1.262 N/A
Finasteride 18 rs7241993 0.01109 0.7619 SALL3
Finasteride 22 rs5759167 0.01402 0.7852 BIL/TTLL1
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Table 4 –
Showing the significant single SNP association for the development of prostate cancer and nearby genes in
SELECT trial
Trial arm CHR SNP P OR Nearest Gene
Placebo 1 rs636291 0.003377 0.6929 PEX14
Placebo 2 rs3771570 0.02715 1.404 FARP2
Placebo 6 rs4713266 0.01558 0.7583 TNS3
Placebo 8 rs1512268 0.05006 1.252 NKX3.1
Placebo 10 rs2252004 0.04196 0.683 N/A
Placebo 11 rs11214775 0.02261 0.7473 HTR3B
Placebo 12 rs1270884 0.04148 0.7919 TBX5
Placebo 17 rs1859962 0.002107 1.422 N/A
Placebo 23 rs5919432 0.006584 1.712 AR
Selenium 2 rs12621278 0.0256 0.563 ITGA6
Selenium 5 rs2242652 0.05695 0.7398 TERT
Selenium 8 rs2928679 0.04767 1.268 SLC25A37
Selenium 10 rs10993994 0.01418 1.345 MSMB
Selenium 10 rs2252004 0.05719 1.465 N/A
Selenium 11 rs1938781 0.0172 0.699 FAM111A
Selenium 12 rs80130819 0.03519 0.6222 N/A
Selenium 17 rs1859962 0.04747 1.267 N/A
Selenium 20 rs6062509 0.01023 0.7144 ZGPAT
Vit E 3 rs2660753 0.00565 1.659 N/A
Vit E 4 rs7679673 0.01517 0.7443 TET2
Vit E 6 rs2273669 0.04909 1.383 ARMC2, SESN1
Vit E 8 rs1512268 0.04919 1.261 NKX3.1
Vit E 10 rs10993994 0.03971 1.28 MSMB
Vit E 11 rs11214775 0.001709 0.661 HTR3B
Vit E 11 rs1938781 0.02891 0.7233 FAM111A
Vit E 11 rs7127900 0.03343 1.365 N/A
Vit E 11 rs7931342 0.03694 0.7825 N/A
Vit E 17 rs138213197 0.05212 3.532 N/A
Sel + Vit E 2 rs12621278 0.01127 0.5422 ITGA6
Sel + Vit E 2 rs10187424 0.03605 1.264 GGCX/VAMP8
Sel + Vit E 2 rs11902236 0.0422 1.275 TAF1B:GRHL1
Sel + Vit E 8 rs1447295 0.0118 1.556 N/A
Sel + Vit E 8 rs620861 0.01228 0.7508 N/A
Sel + Vit E 8 rs12543663 0.04453 1.273 N/A
Sel + Vit E 9 rs1571801 0.02191 0.7455 DAB21P (aggressive SNP)
Sel + Vit E 11 rs11568818 0.01959 0.7711 MMP7
Sel + Vit E 14 rs8014671 0.05637 1.237 N/A
Sel + Vit E 17 rs1859962 0.05754 1.234 N/A
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Trial arm CHR SNP P OR Nearest Gene
Sel + Vit E 20 rs2427345 0.05815 0.8051 GATAS, CABLES2
Sel + Vit E 23 rs5945619 0.000263 1.808 NUDT11
Sel + Vit E 23 rs2405942 0.0367 0.6727 SHROOM2
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Table 5 –
Showing the significant single SNP association of high and low grade Gleason score and nearby genes in
PCPT and SELECT trial
Trial CHR SNP P OR Nearest Gene
SELECT 1 rs1218582 0.2969 0.8991 N/A
SELECT 1 rs636291 0.000788 0.6965 PEX14
PCPT 2 rs721048 0.02 1.487 EHBP1
SELECT 2 rs12621278 0.009552 0.563 ITGA6
SELECT 2 rs3771570 0.02863 1.35 FARP2
PCPT 3 rs2055109 0.01 0.6528 N/A
SELECT 3 rs2660753 0.00946 1.505 N/A
SELECT 3 rs10934853 0.01466 1.316 N/A
PCPT 5 rs2853676 0.04 1.368 N/A
PCPT 5 rs13190087 0.01 2.398 N/A
SELECT 5 rs2242652 0.02988 0.7401 TERT
PCPT 6 rs2273669 0.02 1.535 ARMC2, SESN1
SELECT 6 rs2273669 0.03273 1.324 ARMC2, SESN1
SELECT 6 rs2273669 0.03308 1.355 ARMC2, SESN1
SELECT 7 rs12155172 0.0316 1.281 N/A
PCPT 8 rs620861 0.02 0.6856 N/A
PCPT 8 rs11135910 0.05 0.6722 EBF2
SELECT 8 rs12543663 0.04911 1.24 N/A
SELECT 8 rs1512268 0.02339 1.254 NKX3.1
SELECT 8 rs1447295 0.02999 1.387 8q24
SELECT 8 rs16901979 0.003904 2.109 N/A
PCPT 10 rs3850699 0.04 1.343 TRIM8
SELECT 10 rs10993994 0.008375 1.315 MSMB
SELECT 10 rs2252004 0.003301 0.6115 N/A
PCPT 11 rs7127900 0.04 0.6679 N/A
PCPT 11 rs1938781 0.04 1.386 FAM111A
SELECT 11 rs1938781 0.01914 0.7441 FAM111A
SELECT 11 rs11214775 0.000796 0.6819 HTR3B
SELECT 11 rs11568818 0.01808 0.7962 MMP7
PCPT 12 rs10875943 0.02 1.439 TUBA1C/PRPH
SELECT 12 rs1270884 0.04893 0.8222 TBX5
SELECT 12 rs80130819 0.01114 0.6233 N/A
SELECT 14 rs8014671 0.03711 1.224 N/A
SELECT 17 rs1859962 0.004161 1.328 N/A
SELECT 17 rs138213197 0.005718 NA N/A
SELECT 17 rs1859962 0.009122 1.3 N/A
SELECT 20 rs6062509 0.001863 0.71 ZGPAT
SELECT 22 rs5759167 0.02545 0.8011 N/A
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Trial CHR SNP P OR Nearest Gene
SELECT 22 rs9623117 0.03146 0.7666 N/A
SELECT 23 rs5919432 0.003371 1.662 AR
SELECT 23 rs5945619 3.75E-05 1.784 NUDT11
SELECT 23 rs2405942 0.01501 0.6641 SHROOM2
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Table 6 –
Polygenic risk score analyses results. P value corresponding to beta estimate. Weighted polygenic risk score
weighted by log odds ratio
Beta P
Unweighted Polygenic Risk Score PCPT
SNP Score Category 2 0.45 0.001
SNP Score Category 3 0.67 3E-06
SNP Score Category 4 1.01 8E-15
Drug 0.09 0.33
Weighted Polygenic Risk Score PCPT
SNP Score Category 2 0.4 0.01
SNP Score Category 3 0.57 0.00002
SNP Score Category 4 0.79 1E-08
Drug 0.1 0.29
Unweighted Polygenic Risk Score SELECT
SNP Score Category 2 0.13 0.6
SNP Score Category 3 0.08 0.68
SNP Score Category 4 0.2 0.31
Selenium 0.21 0.28
Vitamin E 0.13 0.5
Selenium & Vitamin E 0.08 0.7
Weighted Polygenic Risk Score SELECT
SNP Score Category 2 0.23 0.04
SNP Score Category 3 0.23 0.04
SNP Score Category 4 0.52 5E-08
Selenium −0.04 0.66
Vitamin E 0.07 0.48
Selenium & Vitamin E 0 0.65
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Table 7 –
Showing weighted polygenic risk score, trial drug and family history predicting Gleason Score
Weighted SNP score to predict Gleason Cat (HG/LG) using Drug and Family History Beta P1
PCPT
SNP Score Category 2 0.44 0.11
SNP Score Category 3 0.41 0.1
SNP Score Category 4 0.14 0.57
Drug 0.69 0.0000007
Family History −0.02 0.9
SELECT
SNP Score Category 2 −0.56 0.003
SNP Score Category 3 −0.17 0.33
SNP Score Category 4 −0.28 0.08
Selenium 0 1
Vitamin E 0.03 0.84
Selenium & Vitamin E −0.09 0.6
Family History −0.15 0.23
Prostate Cancer Prostatic Dis. Author manuscript.
